CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 162 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2021. The put-call ratio across all filers is 0.67 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $63,099,260 | -31.8% | 2,292,851 | -15.9% | 0.00% | -40.0% |
| Q2 2023 | $92,537,493 | +11.7% | 2,727,306 | +18.4% | 0.01% | 0.0% |
| Q1 2023 | $82,844,558 | -59.4% | 2,302,525 | -49.8% | 0.01% | -16.7% |
| Q4 2022 | $204,260,210 | +129.1% | 4,582,908 | +44.5% | 0.01% | 0.0% |
| Q3 2022 | $89,153,000 | +2.4% | 3,171,578 | -1.8% | 0.01% | +20.0% |
| Q2 2022 | $87,050,000 | -4.7% | 3,228,852 | +20.4% | 0.01% | 0.0% |
| Q1 2022 | $91,374,000 | -0.1% | 2,682,728 | +13.3% | 0.01% | +25.0% |
| Q4 2021 | $91,501,000 | -8.7% | 2,368,040 | +27.5% | 0.00% | -20.0% |
| Q3 2021 | $100,266,000 | +43.2% | 1,857,118 | -11.3% | 0.01% | +25.0% |
| Q2 2021 | $70,031,000 | +81.1% | 2,094,218 | +11.6% | 0.00% | +100.0% |
| Q1 2021 | $38,666,000 | +21.9% | 1,876,977 | +3.7% | 0.00% | 0.0% |
| Q4 2020 | $31,716,000 | +8335.1% | 1,810,260 | +7030.7% | 0.00% | – |
| Q3 2020 | $376,000 | – | 25,387 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 1,017,524 | $20,961,000 | 7.56% |
| Octagon Capital Advisors LP | 561,398 | $11,565,000 | 4.36% |
| COMMODORE CAPITAL LP | 369,951 | $7,621,000 | 3.04% |
| Opaleye Management Inc. | 985,000 | $20,291,000 | 2.98% |
| VR Adviser, LLC | 1,240,610 | $25,557,000 | 2.77% |
| TSP Capital Management Group, LLC | 359,229 | $7,400,000 | 2.61% |
| RTW INVESTMENTS, LP | 3,908,947 | $80,524,000 | 1.26% |
| Ghost Tree Capital, LLC | 250,000 | $5,150,000 | 1.21% |
| Tri Locum Partners LP | 196,672 | $4,051,000 | 1.00% |
| Redmile Group, LLC | 3,387,788 | $69,788,000 | 0.98% |